- Home
- OTLK vs RNA Comparison
OTLK vs RNA Comparison
Compare OTLK & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OTLK | RNA |
|---|---|---|
| Founded | 2010 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.6M | 222.5M |
| IPO Year | 2016 | 2025 |
Fundamental Metrics
Financial Performance| Metric | OTLK | RNA |
|---|---|---|
| Price | $1.41 | $12.14 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 20 |
| Target Price | $2.50 | ★ $69.26 |
| AVG Volume (30 Days) | ★ 11.8M | 229.2K |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.91 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,146,123.00 | N/A |
| Revenue This Year | $1,430.98 | $88.12 |
| Revenue Next Year | $173.23 | $18.11 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $11.40 |
| 52 Week High | $3.39 | $73.06 |
Technical Indicators
Market Signals| Indicator | OTLK | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 50.35 | 40.63 |
| Support Level | $1.21 | $11.95 |
| Resistance Level | $1.54 | $14.05 |
| Average True Range (ATR) | 0.18 | 0.52 |
| MACD | -0.06 | -0.10 |
| Stochastic Oscillator | 17.54 | 14.17 |
Price Performance
Historical ComparisonAbout OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About RNA Avidity Biosciences Inc.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.